InsiderTrades

Form 4 for RMD ResMed|

Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-08 · accession 0000943819-25-000187 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-12-09 2025-12-08 RMD Farrell Michael J. COB, CEO, Dir M - OptEx $146.34 +4,991 471.2K +1% +$730.4K
D 2025-12-09 2025-12-08 RMD Farrell Michael J. COB, CEO, Dir S - Sale+OE $251.41 -4,991 466.2K -1% -$1.25M
D 2025-12-09 2025-12-08 RMD Farrell Michael J. COB, CEO, Dir M - OptEx $0.00 -4,991 54.9K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common ResMed Common Stock 2025-12-08 M A 4,991 $146.34 471,214 D — —
2 Common ResMed Common Stock 2025-12-08 S D 4,991 $251.41 466,223 D — — (F2) This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price.
3 Derivative ResMed Common Stock Options 2025-12-08 M D 4,991 $0.00 54,903 D $146.34 · 2020-11-11 to 2026-11-21 4,991 ResMed Common Stock (F3) Represents date options first become exercisable. Options vest 1/3 per year.